DE60138876D1 - Geschmackmaskierte granulierte teilchen - Google Patents

Geschmackmaskierte granulierte teilchen

Info

Publication number
DE60138876D1
DE60138876D1 DE60138876T DE60138876T DE60138876D1 DE 60138876 D1 DE60138876 D1 DE 60138876D1 DE 60138876 T DE60138876 T DE 60138876T DE 60138876 T DE60138876 T DE 60138876T DE 60138876 D1 DE60138876 D1 DE 60138876D1
Authority
DE
Germany
Prior art keywords
pellets
granulated particles
taste
active compound
masked
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60138876T
Other languages
English (en)
Inventor
Franz Xaver Schwarz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG filed Critical Sandoz AG
Application granted granted Critical
Publication of DE60138876D1 publication Critical patent/DE60138876D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Seasonings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • General Preparation And Processing Of Foods (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60138876T 2000-03-28 2001-03-26 Geschmackmaskierte granulierte teilchen Expired - Lifetime DE60138876D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT5242000 2000-03-28
PCT/EP2001/003409 WO2001072284A1 (en) 2000-03-28 2001-03-26 Granulated particles with masked taste

Publications (1)

Publication Number Publication Date
DE60138876D1 true DE60138876D1 (de) 2009-07-16

Family

ID=3675949

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60138876T Expired - Lifetime DE60138876D1 (de) 2000-03-28 2001-03-26 Geschmackmaskierte granulierte teilchen

Country Status (17)

Country Link
US (3) US20030099715A1 (de)
EP (1) EP1267840B1 (de)
KR (1) KR20030011797A (de)
AT (1) ATE432691T1 (de)
AU (2) AU6381201A (de)
BR (1) BR0109544A (de)
CA (1) CA2403757A1 (de)
DE (1) DE60138876D1 (de)
DK (1) DK1267840T3 (de)
HK (1) HK1051148A1 (de)
HR (1) HRP20020781A2 (de)
IL (1) IL151888A0 (de)
IS (1) IS6553A (de)
MX (1) MXPA02009587A (de)
NZ (1) NZ521368A (de)
WO (1) WO2001072284A1 (de)
ZA (1) ZA200207737B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168228B2 (en) 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
WO2006030297A1 (en) * 2004-09-17 2006-03-23 Ranbaxy Laboratories Limited Taste masked granules comprising clarithromycin, hydrocolloids and a coating
FR2911506B1 (fr) * 2007-01-18 2009-07-03 Ceva Sante Animale Sa Compositions pharmaceutiques destinees a une administration par voie orale sous forme de suspensions aqueuses stabilisees
US8999395B2 (en) 2007-02-09 2015-04-07 Ceva Sante Animale Pharmaceutical compositions for oral administration in the form of stabilised aqueous suspensions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
WO2015166473A1 (en) * 2014-05-01 2015-11-05 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
WO2016016845A1 (en) 2014-07-30 2016-02-04 Sun Pharmaceutical Industries Limited Dual-chamber pack
WO2016154313A1 (en) * 2015-03-24 2016-09-29 Zywie, Llc High drug loading liquid oral pharmaceutical compositions
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331803A (en) * 1980-06-04 1982-05-25 Taisho Pharmaceutical Co., Ltd. Novel erythromycin compounds
JPS59104326A (ja) * 1982-12-04 1984-06-16 Toyo Jozo Co Ltd マクロライド抗生物質の安定な経口用製剤および安定化法
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
JPS61103890A (ja) * 1984-10-26 1986-05-22 Taisho Pharmaceut Co Ltd ６−０−メチルエリスロマイシンａ誘導体
US4640910A (en) * 1985-11-12 1987-02-03 Abbott Laboratories Erythromycin A silylated compounds and method of use
US4833236A (en) * 1986-05-02 1989-05-23 Taisho Pharmaceutical Co., Ltd. Erythromycin derivatives
DE3782994T2 (de) * 1986-09-18 1993-04-08 Taisho Pharma Co Ltd Erythromycin-a-derivate und verfahren zu ihrer herstellung.
US4800087A (en) * 1986-11-24 1989-01-24 Mehta Atul M Taste-masked pharmaceutical compositions
US5811088A (en) * 1987-02-20 1998-09-22 Emory University Antiinfective compounds and methods of use
US5674911A (en) * 1987-02-20 1997-10-07 Cytrx Corporation Antiinfective polyoxypropylene/polyoxyethylene copolymers and methods of use
KR880009960A (ko) * 1987-02-24 1988-10-06 데이빗 로버츠 화학적 화합물
US4808411A (en) * 1987-06-05 1989-02-28 Abbott Laboratories Antibiotic-polymer compositions
US5874164A (en) * 1988-03-14 1999-02-23 Nextec Applications, Inc. Barrier webs having bioactive surfaces
US6040251A (en) * 1988-03-14 2000-03-21 Nextec Applications Inc. Garments of barrier webs
US5856245A (en) * 1988-03-14 1999-01-05 Nextec Applications, Inc. Articles of barrier webs
US4925675A (en) * 1988-08-19 1990-05-15 Himedics, Inc. Erythromycin microencapsulated granules
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
US5085864A (en) * 1989-10-30 1992-02-04 Abbott Laboratories Injectable formulation for lipophilic drugs
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
WO1992006991A1 (fr) * 1990-10-15 1992-04-30 Taisho Pharmaceutical Co., Ltd. Erythromycine modifiee en 2' ou derive de cette substance
KR0166096B1 (ko) * 1990-11-28 1999-01-15 우에하라 아키라 6-0-메틸에리쓰로마이신 a 유도체
US5599556A (en) * 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
TW276996B (de) * 1992-04-24 1996-06-01 Astra Ab
US6043225A (en) * 1992-06-12 2000-03-28 Board Of Regents Of The University Of Washington Diagnosis and treatment of arterial chlamydial granuloma
US5811547A (en) * 1992-10-14 1998-09-22 Nippon Shinyaju Co., Ltd. Method for inducing crystalline state transition in medicinal substance
US5356634A (en) * 1992-11-13 1994-10-18 Eastman Chemical Company Controlled-release delivery system
ATE181672T1 (de) * 1993-04-28 1999-07-15 Takeda Chemical Industries Ltd Geschmacksmaskierte feste zubereitung und verfahren zur herstellung
FR2713226B1 (fr) * 1993-12-03 1996-01-05 Roussel Uclaf Nouveaux dérivés de l'érythromycine, leur procédé de préparation et leur application comme médicaments.
ES2199981T3 (es) * 1994-02-16 2004-03-01 Abbott Laboratories Modo de preparacion de formulaciones farmaceuticas de particulas finas.
EP0758549A4 (de) * 1994-04-26 1997-07-02 Nobuhiro Narita Medizinische zusammensetzung als medikament gegen nicht kleinzelligen lungenkrebs
EP0689840A1 (de) * 1994-06-28 1996-01-03 Spirig Ag Pharmazeutische Präparate Neues orales Erythromycinbase enthaltendes Arzneimittel
US5498424A (en) * 1994-11-30 1996-03-12 Klein; Ira Method of treating obesity
US5760010A (en) * 1995-01-01 1998-06-02 Klein; Ira Method of treating liver disorders with a macrolide antibiotic
US6379651B1 (en) * 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US5972373A (en) * 1995-05-02 1999-10-26 Taisho Pharmaceutical Co., Ltd. Taste masking pharmaceutical composition for oral administration
US5786338A (en) * 1995-06-28 1998-07-28 Klein; Ira Method of treating hypercholesterolemia with a macrolide antibiotic
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US5919489A (en) * 1995-11-01 1999-07-06 Abbott Laboratories Process for aqueous granulation of clarithromycin
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5885601A (en) * 1996-04-05 1999-03-23 Family Health International Use of macrolide antibiotics for nonsurgical female sterilization and endometrial ablation
US5808017A (en) * 1996-04-10 1998-09-15 Abbott Laboratories Process for preparing erythromycin A oxime
US5958888A (en) * 1996-07-02 1999-09-28 Merial, Inc. Water miscible macrolide solutions
US5844105A (en) * 1996-07-29 1998-12-01 Abbott Laboratories Preparation of crystal form II of clarithromycin
US5858986A (en) * 1996-07-29 1999-01-12 Abbott Laboratories Crystal form I of clarithromycin
US5853740A (en) * 1996-08-07 1998-12-29 Abbott Laboratories Delivery system for pharmaceutical agents encapsulated with oils
US5795563A (en) * 1996-09-04 1998-08-18 Sphingomonas Research Partners, L.P. Identification of an exogenous intra-erythrocytic bacterium in patients having systemic lupus erythematosus, and treatment
US6400374B2 (en) * 1996-09-18 2002-06-04 Eyematic Interfaces, Inc. Video superposition system and method
GB2318511A (en) * 1996-10-23 1998-04-29 Eurand Int Process for the preparation of a pharmaceutical composition for rapid suspension in water
US8828432B2 (en) * 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
US5945405A (en) * 1997-01-17 1999-08-31 Abbott Laboratories Crystal form O of clarithromycin
US6551632B2 (en) * 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
ES2303351T3 (es) * 1997-04-01 2008-08-01 Thomas Julius Borody Metodos y composiciones para tratar enfermedades intestinales inflamatorias.
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
US6406880B1 (en) * 1997-05-02 2002-06-18 Integrated Research Technology, Llc Betaines as adjuvants to susceptibility testing and antimicrobial therapy
AU729529B2 (en) * 1997-06-06 2001-02-01 Depomed, Inc. Gastric-retentive oral drug dosage forms for controlled release of highly soluble drugs
US6054133A (en) * 1997-07-10 2000-04-25 The Regents Of The University Of California Anti-microbial targeting for intracellular pathogens
SI9700186B (sl) * 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
EP0895999A1 (de) * 1997-08-06 1999-02-10 Pfizer Products Inc. C-4"-substituierte Macrolidantibiotica
US6174865B1 (en) * 1997-09-25 2001-01-16 Ira Klein Method of treating hypertriglyceridemia with an erythromycin compound
US5928174A (en) * 1997-11-14 1999-07-27 Acrymed Wound dressing device
US5955440A (en) * 1998-03-27 1999-09-21 Abbott Laboratories Macrolide LHRH antagonists
US5972898A (en) * 1998-03-27 1999-10-26 Abbott Laboratories 3',3-N-bis-substituted macrolide LHRH antagonists
DE19814257A1 (de) * 1998-03-31 1999-10-07 Asta Medica Ag Brauseformulierungen
HRP980189B1 (en) * 1998-04-06 2004-04-30 Pliva Pharm & Chem Works Novel 15-membered lactams ketolides
US6015803A (en) * 1998-05-04 2000-01-18 Wirostko; Emil Antibiotic treatment of age-related macular degeneration
US6322532B1 (en) * 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
US20020107174A1 (en) * 1998-07-02 2002-08-08 Erik J. Paus Composition comprising endotoxin neutralizing protein and derivatives and uses thereof
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
US7303768B2 (en) * 1998-07-24 2007-12-04 Seo Hong Yoo Preparation of aqueous clear solution dosage forms with bile acids
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
US20020106357A1 (en) * 1998-09-24 2002-08-08 Ira Shafran Crohn's disease treatment methods
AU760884B2 (en) * 1998-10-20 2003-05-22 Russinsky Limited Derivatives of erythromycin, clarithromycin, roxithromycin or azithromycin with antibiotic and mucolytic activity
US6357323B2 (en) * 1998-11-16 2002-03-19 Yuan-Ching Chi Wrench
US6093417A (en) * 1999-01-11 2000-07-25 Advanced Medical Instruments Composition to treat ear disorders
IN190017B (de) * 1999-01-25 2003-05-31 Panacea Biotech Ltd
IL133077A0 (en) * 1999-01-29 2001-03-19 Pfizer Prod Inc Azithromycin combination for emesis control in dogs
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
US6383471B1 (en) * 1999-04-06 2002-05-07 Lipocine, Inc. Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
SI20244A (sl) * 1999-05-19 2000-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Granulacija v talini
PT1194124E (pt) * 1999-06-11 2004-02-27 Ranbaxy Lab Ltd Composicoes de sabor mascarado
CA2282066C (en) * 1999-06-29 2010-09-07 Smithkline Beecham Corporation Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
US6228400B1 (en) * 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
US20020068761A1 (en) * 1999-10-04 2002-06-06 Bernstein Lawrence R. Gallium complexes of 3-hydroxy-4-pyrones to treat mycobacterial infections
US6720001B2 (en) * 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
CZ20021999A3 (cs) * 1999-12-16 2003-02-12 Teva Pharmaceutical Industries Ltd. Způsob přípravy klaritromycinových polymorfních forem a nového polymorfu IV
PL356645A1 (en) * 2000-01-11 2004-06-28 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin polymorphs
AU2578701A (en) * 2000-02-29 2001-09-12 Teva Pharma Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
AU771825B2 (en) * 2000-03-15 2004-04-01 Hanmi Pharm. Co., Ltd. Method of preparing clarithromycin of form II crystals
US20010041706A1 (en) * 2000-03-24 2001-11-15 Synold Timothy W. Blockade of taxane metabolism
US6761895B2 (en) * 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
AU5967101A (en) * 2000-05-10 2001-11-20 Rtp Pharma Inc Media milling
US20020042394A1 (en) * 2000-05-31 2002-04-11 Hogenkamp Henricus P.C. Cobalamin compounds useful as antibiotic agents and as imaging agents
US20020013270A1 (en) * 2000-06-05 2002-01-31 Bolte Ellen R. Method for treating a mental disorder
CN1176935C (zh) * 2000-06-20 2004-11-24 王新华 克拉霉素2′-单丙酸酯十二烷基硫酸盐制备及其药用
US6375982B1 (en) * 2000-07-05 2002-04-23 Capricorn Pharma, Inc. Rapid-melt semi-solid compositions, methods of making same and method of using same
CA2417389C (en) * 2000-07-27 2012-05-29 Rutgers, The State University Therapeutic polyesters and polyamides
US20020032245A1 (en) * 2000-07-27 2002-03-14 Lyn Hughes Resinate composition
US20020115621A1 (en) * 2000-08-07 2002-08-22 Wei-Gu Su Macrolide antibiotics
IN192748B (de) * 2000-08-29 2004-05-15 Ranbaxy Lab Ltd
US6452879B1 (en) * 2000-09-29 2002-09-17 Fujitsu Limited Optical storage apparatus

Also Published As

Publication number Publication date
WO2001072284A1 (en) 2001-10-04
US20050220871A1 (en) 2005-10-06
MXPA02009587A (es) 2003-05-14
HRP20020781A2 (en) 2004-12-31
BR0109544A (pt) 2003-06-10
NZ521368A (en) 2004-05-28
EP1267840B1 (de) 2009-06-03
AU6381201A (en) 2001-10-08
DK1267840T3 (da) 2009-09-07
US20080095855A1 (en) 2008-04-24
ATE432691T1 (de) 2009-06-15
IL151888A0 (en) 2003-04-10
US20030099715A1 (en) 2003-05-29
KR20030011797A (ko) 2003-02-11
ZA200207737B (en) 2003-05-08
EP1267840A1 (de) 2003-01-02
CA2403757A1 (en) 2001-10-04
IS6553A (is) 2002-09-18
AU2001263812B2 (en) 2004-09-23
HK1051148A1 (en) 2003-09-26

Similar Documents

Publication Publication Date Title
DE60138876D1 (de) Geschmackmaskierte granulierte teilchen
WO2007000778A3 (en) Modified release pharmaceutical compositions on the basis of two polymers and processes thereof
AU2003231126A1 (en) Chewable soft capsule
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
HK1115308A1 (en) Solid dosage form comprising proton pump inhibitor and suspension made thereof
WO2006035417A3 (en) Dihydropyrimidine microcapsule - formulations
NO962040L (no) Mikroinnkapslede 3-piperidinyl-substituerte 1,2-benzisoksazoler og 1,2-benzisotiazoler
PH26317A (en) Modified release gemfibrozil composition
HK1084582A1 (en) Stable solid medicinal composition for oral administration
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2001022791A8 (en) Controlled release compositions comprising nimesulide
NO20052408L (no) Farmasoytisk formulering av olanzapin
GEP20043285B (en) Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
EA200401298A1 (ru) Жидкие фармацевтические композиции, содержащие низкую дозу энтекавира, и их применение
DE60030283D1 (de) Zusammensetzungen zur erhöhung der bioverfügbarkeit von oral verabreichten pharmazeutischen verbindungen
DK1142573T3 (da) Farmaceutiske præparater omfattende faropenem-natrium og en diaminacetatforbindelse til forbedring af absorption i mave-tarm-kanalen
GB2426707A (en) A stable parental formulation of levomepromazine and a method for stabilizing said formulation
DK1461017T3 (da) Farmaceutisk sammensætning til styret frigivelse af et beta-lactam-antibiotikum
JP2022062153A5 (de)
ME00088B (me) Farmaceutski preparat i njegova priprema
DE69907479D1 (de) Piroxicam enthaltende gastrointestinale Zubereitung aus merheren Einheiten bestehend
SE0103613D0 (sv) Novel formulation
BRPI0506715A (pt) composição farmacêutica para liberação controlada que compreende um polìmero insolúvel em ácido e um polìmero bioadesivo
CA2617351A1 (en) Diltiazem controlled release formulation and method of manufacture
WO2001003774A3 (en) Pharmaceutical composition for the treatment of calcification

Legal Events

Date Code Title Description
8364 No opposition during term of opposition